Toll-Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression

Table 1

Antibody of CII in serum (, ).

Group	CII(ng/ml)
Control	10.59±2.20
Shikonin-high	5.27±2.00
Shikonin- medium	7.02±2.24
Shikonin-low	7.42±1.28
Celecoxib	9.45±1.20

Note: ^∗P <0.05, ^∗∗P <0.01 versus controls.